Fintel reports that on April 29, 2025, Cantor Fitzgerald initiated coverage of BioCryst Pharmaceuticals (NasdaqGS:BCRX) with ...

Studies of treatment with neuraminidase inhibitors have not shown sufficient evidence that they prevent transmission to contacts. We conducted a multicountry, phase 3b trial to assess the efficacy ...

Roche is hoping the new drug can breathe new life into its flu franchise, represented by older neuraminidase inhibitor Tamiflu (oseltamivir). That was a $3 billion brand at its peak, but has ...